Clinical features of carcinoid syndrome and the use of somatostatin analogue in its management

A. I. Vinik, N. Thompson, Frederic Eckhauser, A. R. Moattari

Research output: Contribution to journalArticle

Abstract

A review is given on the clinical features of carcinoid syndrome including symtomatology, diagnostics, biochemistry and treatment. We have reviewed the literature on current therapy of carcinoid patients with special emphasis on the use of the somatostatin analogue SMS 20-1995. In addition, we present data on the effects of SMS 201-995 on indices of a clinical, biochemical and tumor growth. Diarrhea is abolished or significantly reduced in 75% of patients, flushing improves in 100% wheezing in 100% with a decrease in airways resistance, and in one patient myopathy has improved. Blood serotonin is notoriously resistant to intervention and urinary 5-HIAA will decrease in 75% of causes but subsequently rebounds in 38% Tumors, in general, continue to grow, but this may be slowed or in rare cases tumor growth is arrested. In individual instances the tumor may even infarct, leading to spontaneous cure. Tumors secreting PP, ACTH and calcitonin may be particularly resistant to treatment, whereas VIP secreting tumors appear to be sensitive.

Original languageEnglish (US)
Pages (from-to)389-402
Number of pages14
JournalActa Oncologica
Volume28
Issue number3
DOIs
StatePublished - 1989
Externally publishedYes

Fingerprint

Carcinoid Tumor
Somatostatin
Neoplasms
Hydroxyindoleacetic Acid
Airway Resistance
Octreotide
Respiratory Sounds
Calcitonin
Muscular Diseases
Growth
Biochemistry
Adrenocorticotropic Hormone
Diarrhea
Serotonin
Therapeutics

Keywords

  • Carcinoid syndrome
  • Clinical features
  • Somatostatin analogue

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Hematology

Cite this

Clinical features of carcinoid syndrome and the use of somatostatin analogue in its management. / Vinik, A. I.; Thompson, N.; Eckhauser, Frederic; Moattari, A. R.

In: Acta Oncologica, Vol. 28, No. 3, 1989, p. 389-402.

Research output: Contribution to journalArticle

Vinik, A. I. ; Thompson, N. ; Eckhauser, Frederic ; Moattari, A. R. / Clinical features of carcinoid syndrome and the use of somatostatin analogue in its management. In: Acta Oncologica. 1989 ; Vol. 28, No. 3. pp. 389-402.
@article{e980d64feab04f21935869b176b5bf8e,
title = "Clinical features of carcinoid syndrome and the use of somatostatin analogue in its management",
abstract = "A review is given on the clinical features of carcinoid syndrome including symtomatology, diagnostics, biochemistry and treatment. We have reviewed the literature on current therapy of carcinoid patients with special emphasis on the use of the somatostatin analogue SMS 20-1995. In addition, we present data on the effects of SMS 201-995 on indices of a clinical, biochemical and tumor growth. Diarrhea is abolished or significantly reduced in 75{\%} of patients, flushing improves in 100{\%} wheezing in 100{\%} with a decrease in airways resistance, and in one patient myopathy has improved. Blood serotonin is notoriously resistant to intervention and urinary 5-HIAA will decrease in 75{\%} of causes but subsequently rebounds in 38{\%} Tumors, in general, continue to grow, but this may be slowed or in rare cases tumor growth is arrested. In individual instances the tumor may even infarct, leading to spontaneous cure. Tumors secreting PP, ACTH and calcitonin may be particularly resistant to treatment, whereas VIP secreting tumors appear to be sensitive.",
keywords = "Carcinoid syndrome, Clinical features, Somatostatin analogue",
author = "Vinik, {A. I.} and N. Thompson and Frederic Eckhauser and Moattari, {A. R.}",
year = "1989",
doi = "10.3109/02841868909111212",
language = "English (US)",
volume = "28",
pages = "389--402",
journal = "Acta Oncologica",
issn = "0284-186X",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Clinical features of carcinoid syndrome and the use of somatostatin analogue in its management

AU - Vinik, A. I.

AU - Thompson, N.

AU - Eckhauser, Frederic

AU - Moattari, A. R.

PY - 1989

Y1 - 1989

N2 - A review is given on the clinical features of carcinoid syndrome including symtomatology, diagnostics, biochemistry and treatment. We have reviewed the literature on current therapy of carcinoid patients with special emphasis on the use of the somatostatin analogue SMS 20-1995. In addition, we present data on the effects of SMS 201-995 on indices of a clinical, biochemical and tumor growth. Diarrhea is abolished or significantly reduced in 75% of patients, flushing improves in 100% wheezing in 100% with a decrease in airways resistance, and in one patient myopathy has improved. Blood serotonin is notoriously resistant to intervention and urinary 5-HIAA will decrease in 75% of causes but subsequently rebounds in 38% Tumors, in general, continue to grow, but this may be slowed or in rare cases tumor growth is arrested. In individual instances the tumor may even infarct, leading to spontaneous cure. Tumors secreting PP, ACTH and calcitonin may be particularly resistant to treatment, whereas VIP secreting tumors appear to be sensitive.

AB - A review is given on the clinical features of carcinoid syndrome including symtomatology, diagnostics, biochemistry and treatment. We have reviewed the literature on current therapy of carcinoid patients with special emphasis on the use of the somatostatin analogue SMS 20-1995. In addition, we present data on the effects of SMS 201-995 on indices of a clinical, biochemical and tumor growth. Diarrhea is abolished or significantly reduced in 75% of patients, flushing improves in 100% wheezing in 100% with a decrease in airways resistance, and in one patient myopathy has improved. Blood serotonin is notoriously resistant to intervention and urinary 5-HIAA will decrease in 75% of causes but subsequently rebounds in 38% Tumors, in general, continue to grow, but this may be slowed or in rare cases tumor growth is arrested. In individual instances the tumor may even infarct, leading to spontaneous cure. Tumors secreting PP, ACTH and calcitonin may be particularly resistant to treatment, whereas VIP secreting tumors appear to be sensitive.

KW - Carcinoid syndrome

KW - Clinical features

KW - Somatostatin analogue

UR - http://www.scopus.com/inward/record.url?scp=0024319702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024319702&partnerID=8YFLogxK

U2 - 10.3109/02841868909111212

DO - 10.3109/02841868909111212

M3 - Article

VL - 28

SP - 389

EP - 402

JO - Acta Oncologica

JF - Acta Oncologica

SN - 0284-186X

IS - 3

ER -